Findings

What do systematic reviews say?

4,783 questions · 10,022 findings · 882 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,100 · 21%GRADE not reported 1,013 · 10.1%Very low 2,237 · 22.3%Low 2,514 · 25.1%Moderate 1,709 · 17.1%High 449 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1139 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1134 participants
High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1134 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1108 participants
High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Time to first pulmonary exacerbation · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1108 participants
Moderate

Specialised cognitive behavioural therapy‐based physiotherapy vs treatment

Reduction in physical signs End of treatment · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

The review found no eligible studies for this question.

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Specialised cognitive behavioural therapy‐based physiotherapy vs treatment

Level of functioning · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Specialised cognitive behavioural therapy‐based physiotherapy vs treatment

Quality of life · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

The review found no eligible studies for this question.

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Specialised cognitive behavioural therapy‐based physiotherapy vs treatment

Adverse events · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

The review found no eligible studies for this question.

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 204 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

Quality of life ‐ total score · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 204 participants
Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 204 participants
Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 204 participants
Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

Time to first pulmonary exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Survival · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 634 participants
Moderate

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: total score · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 382 participants
Moderate

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

FEV1 % predicted: relative change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
6 participants
GRADE not reported